GLP-1 Cross-Sector Digest
TL;DR
The story this stretch is the category's ambition expanding in two directions at once: Novo and Lilly presented aging-clock data suggesting their drugs slow biological aging by two to three years — the logical endpoint of the lifestyle repositioning — while the oral script war showed both a breakout and a pullback in the same two weeks. Viking kept the maintenance-optionality thesis alive with its oral maintenance trial, and a new NAION litigation front surfaced in the BMJ just as the MDL Daubert ruling drags past four weeks.
The longevity claim is here: drugmakers say GLP-1s rewind biological age
The TAM conversation just got a new ceiling. At the Aging Research & Drug Discovery conference in Boston, both majors presented molecular "aging clock" data — Novo from 10,052 people split between semaglutide and placebo, Lilly from epigenetic clocks on tirzepatide — pointing to a drug-versus-placebo difference of roughly two to three years, and as much as four years on a heart-protein clock (MIT Tech Review aging clocks
).
"When you intervene with semaglutide, does it actually move the clocks in any direction? And the answer is yes."
— MIT Tech Review aging clocks (Source: MIT Technology Review, Oct. 6, 2026)
The outside validation is what makes this more than a PR exercise: Steve Horvath, the inventor of aging clocks, called two years "a pretty strong effect" and said it could be evidence the drugs are "geroprotectors, medications that slow or possibly even reverse biologic aging." The de-risking catalyst already exists — ARPA-H put $38 million into a Texas study testing semaglutide in healthy people over 60, with answers expected in a year or two (MIT Tech Review aging clocks). If geroprotection ever becomes a registrable claim, the addressable population shifts from people with obesity to effectively all adults — but note the caveats: Horvath hasn't seen benefit in people who aren't overweight, and Vadim Gladyshev drew the line sharply: "In an unhealthy population, I do think it's an anti-aging drug. But in a healthy population, no one knows."
What to watch: Whether either major announces a formal geroprotection development program or aging-clock biomarker partnership — the first signal that longevity moves from conference talk to the pipeline.
The oral war: Foundayo spiked, then the whole class exhaled
The oral GLP-1 race confirmed its inflection and then showed its volatility in back-to-back weeks. Foundayo's record week — up ~21% to 64,268 scripts on the Martha Stewart ad and the Medicare Bridge's $50 copay — was followed by a 9.9% pullback to 57,920, while the Wegovy pill slipped 1.4% to ~179.5K and has now been pinned between 181K and 184K for five weeks (Fierce Pharma oral tracker
).
"We're seeing early signs of growth in Q3 for Foundayo."
— Fierce Pharma oral tracker (Source: Fierce Pharma Oral GLP-1 Tracker, Oct. 9, 2026)
The structural read matters more than the weekly noise: Lilly's oral share jumped from just under 23% to 26% in two weeks, Ricks says Foundayo is capturing 7 of 10 Medicare Bridge patients, and tirzepatide now holds ~57% of the total GLP-1 market versus ~49.5% a year ago. Critically, Citi's four-week class-level script growth ran +5.4% against a −6.8% decline a year earlier — the pills are expanding the category, not cannibalizing it (Fierce Pharma oral tracker). This extends last cycle's inflection call: the breakout was real, but the Wegovy pill's plateau suggests a first-mover ceiling Novo hasn't solved.
What to watch: Q3 earnings — Lilly on Oct. 29, Novo on Nov. 4 — where the Foundayo ramp and Medicare Bridge run-rate either confirm the trajectory or don't.
Viking is betting the future of obesity drugs on maintenance, not magnitude
Viking's VK2735 strategy took a concrete step forward on Oct. 6 with Part 2 of its maintenance dosing study: ~195 adults get 21 weeks of weekly injectable induction, then transition to daily oral, weekly oral, monthly subcutaneous, or every-other-week subcutaneous maintenance — with results due in 2027 (Viking VK2735 maintenance
).
"We are eager to continue this study with the initiation of Part 2, which will explore multiple regimens, both oral and subcutaneous, with the potential to provide greater optionality and flexibility to best align with a patient's individual weight loss journey."
— Viking VK2735 maintenance (Source: PR Newswire, Oct. 6, 2026)
This builds on the Sept. 22 Part 1 topline showing 90%+ of weight loss retained on less-frequent injectable dosing. Viking isn't claiming peak-efficacy superiority over Lilly or Novo — it's targeting adherence and persistence, the incumbents' commercial weak point. Both VANQUISH Phase 3 trials are fully enrolled (~4,500 and ~1,000 adults), and the oral Phase 3 remains guided for a Q4 2026 start, though it hadn't been announced as of Oct. 12 (Viking VK2735 maintenance).
What to watch: The oral Phase 3 initiation — a slip past Q4 would be the first negative signal on the execution story.
The litigation overhang grew a second front while the first one stalls
The legal picture got more complicated and stayed unresolved at the same time. The BMJ gave front-page treatment to a new docket: dozens of patients suing Lilly and Novo over NAION — a "stroke" of the optic nerve with a baseline incidence of just 2–10 per 100,000 per year, no treatment, and several observational studies linking it to GLP-1s (GLP-1 litigation
).
"Blood flow to the nerve drops, causing sudden, painless (often permanent) vision loss in one eye, often noticed on waking."
— GLP-1 litigation (Source: The BMJ, Oct. 9, 2026)
Meanwhile, the existing binaries are still frozen. Judge Marston's Daubert hearing in MDL-3094 — with 4,022+ pending actions riding on whether plaintiffs' general-causation experts can testify — closed in mid-September with no ruling four weeks later, and Novo's false-advertising injunction motion against Lilly's comparative ads (filed Aug. 17) also remains undecided (GLP-1 litigation). The NAION docket shares the same judge and defendants as the GI-injury MDL, so if causation evidence survives gatekeeping on either front, aggregate settlement tail-risk compounds.
What to watch: The MDL-3094 Daubert opinion, now overdue by mass-tort standards — it's the single gating event for the entire litigation discount.
What surprised us
- The longevity claim came from the drugmakers themselves, not the supplement aisle. Novo and Lilly presenting aging-clock data at ARDD — with Horvath's endorsement — moves "geroprotector" from longevity-Twitter fantasy to something with a $38M ARPA-H trial behind it. That's a faster TAM expansion than any pipeline asset offers.
- The whole class pulled back in the same week. Every major GLP-1 script line declined except Zepbound KwikPen in the Oct. 9 data — a reminder that weekly IQVIA prints are noisy, and the Foundayo "pullback" may be class-level, not competitive.
- Novo's plateau is now five weeks old and unanswered. The Wegovy pill hasn't moved meaningfully since early September, and there's still no sign Novo will answer Lilly's $149 entry pricing before the January list-price cuts.
- The NAION suits chose the right moment to go mainstream. BMJ coverage landing while the Daubert ruling is pending raises the stakes of that opinion — an admission now energizes two dockets, not one.
Open threads worth a vote
GLP-1 Cross-Sector Digest — what changed since last cycle
Since last time
- Promoted — Viking's maintenance thesis. Last cycle it was one clause ("extends last cycle's Viking maintenance thesis"); now it's a full section with a concrete catalyst: Part 2 of the VK2735 maintenance study dosing as of Oct. 6.
- Escalated — The oral script war. The Foundayo inflection you read about last time got its follow-up print: a ~10% pullback, plus new class-level and share data that sharpen the structural read. The litigation overhang also grew: a brand-new NAION docket surfaced via BMJ front-page coverage, layered on top of the two still-frozen binaries.
- Demoted — The lifestyle rebranding. Previously a full section on "customers" vs. "patients"; now it survives only as a passing TL;DR reference — but it's the load-bearing premise behind the new longevity story.
- Disappeared — The amylin/EASD section is gone entirely: no EloraTZP, no CagriSema, no petrelintide/ABBV-295, no Leerink $23B forecast anywhere in this briefing. Same for Novo's $2.6B Hengrui deal (HRS-1596) — the entire "buying optionality" section is absent. And the EloraTZP Phase 3 open thread vanished without resolution (see Open threads).
- Unchanged — Nothing is a pure carryover; every section moved.
[NEW] The longevity claim is here: drugmakers say GLP-1s rewind biological age
This is the biggest new thread. At the Aging Research & Drug Discovery conference in Boston, both majors presented molecular "aging clock" data — Novo from 10,052 people split between semaglutide and placebo, Lilly from epigenetic clocks on tirzepatide — pointing to a drug-versus-placebo difference of roughly two to three years, and as much as four years on a heart-protein clock (MIT Tech Review aging clocks).
"When you intervene with semaglutide, does it actually move the clocks in any direction? And the answer is yes."
— MIT Tech Review aging clocks (Source: MIT Technology Review, Oct. 6, 2026)
What elevates this beyond PR: Steve Horvath — the inventor of aging clocks — called two years "a pretty strong effect" and said it could be evidence the drugs are "geroprotectors, medications that slow or possibly even reverse biologic aging." ARPA-H has already put $38 million into a Texas study testing semaglutide in healthy people over 60, with answers expected in a year or two (MIT Tech Review aging clocks). If geroprotection ever becomes a registrable claim, the addressable population shifts from people with obesity to effectively all adults. Caveats worth holding onto: Horvath hasn't seen benefit in people who aren't overweight, and Vadim Gladyshev drew the line sharply: "In an unhealthy population, I do think it's an anti-aging drug. But in a healthy population, no one knows."
What to watch: Whether either major announces a formal geroprotection development program or aging-clock biomarker partnership — the first signal that longevity moves from conference talk to the pipeline.
[ESCALATED] The oral war: Foundayo spiked, then the whole class exhaled
Last cycle you read the inflection call (+21% to 64,268). The new print adds the other half: a 9.9% pullback to 57,920, while the Wegovy pill slipped 1.4% to ~179.5K and has now been pinned between 181K and 184K for five weeks (Fierce Pharma oral tracker).
"We're seeing early signs of growth in Q3 for Foundayo."
— Fierce Pharma oral tracker (Source: Fierce Pharma Oral GLP-1 Tracker, Oct. 9, 2026)
The structural read got stronger, not weaker: Lilly's oral share jumped from just under 23% to 26% in two weeks, Ricks says Foundayo is capturing 7 of 10 Medicare Bridge patients, and tirzepatide now holds ~57% of the total GLP-1 market versus ~49.5% a year ago. Critically, Citi's four-week class-level script growth ran +5.4% against a −6.8% decline a year earlier — the pills are expanding the category, not cannibalizing it (Fierce Pharma oral tracker). The Wegovy pill's plateau now reads as a first-mover ceiling Novo hasn't solved.
What to watch: Q3 earnings — Lilly on Oct. 29, Novo on Nov. 4 — where the Foundayo ramp and Medicare Bridge run-rate either confirm the trajectory or don't.
[PROMOTED] Viking is betting the future of obesity drugs on maintenance, not magnitude
The maintenance-optionality thesis from last cycle now has a dated catalyst. On Oct. 6, Viking initiated Part 2 of its VK2735 maintenance dosing study: ~195 adults get 21 weeks of weekly injectable induction, then transition to daily oral, weekly oral, monthly subcutaneous, or every-other-week subcutaneous maintenance — with results due in 2027 (Viking VK2735 maintenance).
"We are eager to continue this study with the initiation of Part 2, which will explore multiple regimens, both oral and subcutaneous, with the potential to provide greater optionality and flexibility to best align with a patient's individual weight loss journey."
— Viking VK2735 maintenance (Source: PR Newswire, Oct. 6, 2026)
This builds on the Sept. 22 Part 1 topline showing 90%+ of weight loss retained on less-frequent injectable dosing. Viking isn't claiming peak-efficacy superiority over Lilly or Novo — it's targeting adherence and persistence, the incumbents' commercial weak point. Both VANQUISH Phase 3 trials are fully enrolled (~4,500 and ~1,000 adults), and the oral Phase 3 remains guided for a Q4 2026 start, though it hadn't been announced as of Oct. 12 (Viking VK2735 maintenance).
What to watch: The oral Phase 3 initiation — a slip past Q4 would be the first negative signal on the execution story.
[ESCALATED] The litigation overhang grew a second front while the first one stalls
Both binaries you tracked last time (MDL-3094 Daubert, Novo's Lanham Act injunction) are still frozen — but the docket count went up. The BMJ gave front-page treatment to a new front: dozens of patients suing Lilly and Novo over NAION — a "stroke" of the optic nerve with a baseline incidence of just 2–10 per 100,000 per year, no treatment, and several observational studies linking it to GLP-1s (GLP-1 litigation).
"Blood flow to the nerve drops, causing sudden, painless (often permanent) vision loss in one eye, often noticed on waking."
— GLP-1 litigation (Source: The BMJ, Oct. 9, 2026)
On the existing fronts: Judge Marston's Daubert hearing in MDL-3094 — with 4,022+ pending actions riding on whether plaintiffs' general-causation experts can testify — closed in mid-September with no ruling four weeks later, and Novo's false-advertising injunction motion against Lilly's comparative ads (filed Aug. 17) also remains undecided (GLP-1 litigation). The NAION docket shares the same judge and defendants as the GI-injury MDL, so if causation evidence survives gatekeeping on either front, aggregate settlement tail-risk compounds.
What to watch: The MDL-3094 Daubert opinion, now overdue by mass-tort standards — it's the single gating event for the entire litigation discount.
What surprised us
- [NEW] The longevity claim came from the drugmakers themselves, not the supplement aisle. Novo and Lilly presenting aging-clock data at ARDD — with Horvath's endorsement — moves "geroprotector" from longevity-Twitter fantasy to something with a $38M ARPA-H trial behind it. That's a faster TAM expansion than any pipeline asset offers.
- [NEW] The whole class pulled back in the same week. Every major GLP-1 script line declined except Zepbound KwikPen in the Oct. 9 data — a reminder that weekly IQVIA prints are noisy, and the Foundayo "pullback" may be class-level, not competitive.
- [UPDATED] Novo's plateau is now five weeks old and unanswered. The Wegovy pill hasn't moved meaningfully since early September, and there's still no sign Novo will answer Lilly's $149 entry pricing before the January list-price cuts — extending the pricing standoff flagged last cycle.
- [NEW] The NAION suits chose the right moment to go mainstream. BMJ coverage landing while the Daubert ruling is pending raises the stakes of that opinion — an admission now energizes two dockets, not one.
Open threads
- Closed/absorbed: None — the previous thread (EloraTZP Phase 3 initiation) was not resolved; it simply vanished from this briefing along with the entire amylin section. If you were tracking that catalyst, it's now unmonitored here.
- New thread: [question] Will GLP-1 geroprotection become a formal R&D and regulatory program? — vote on whether the aging-clock data hardens into label attempts, ARPA-H interim reads, or new-patient demographics.